Doseresponse effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: A randomised clinical trial
doi:10.1093/ckj/sfaa054 Jacobson LO, Goldwasser E, Fried W, Plzak L
As an important stakeholder in healthcare, health insurers should play their part in ensuring that GLP-1s, like all other treatments, are being utilized responsibly and at prices that enable financially sustainable treatment plans for the ongoing benefit of all
In the UK, semaglutide (Wegovy) and liraglutide (Saxenda) are licensed specifically for weight management, while semaglutide (Ozempic) is licensed only for type 2 diabetes
Some plans may require prior authorization or place restrictions on coverage, such as requiring patients to have specific medical conditions or to have tried and failed other weight-loss medications first